For international manufacturers
Partnership
MKT Pharma is a pharmaceutical company in Vietnam, dedicated to international manufacturer partnerships. We source quality medicines from manufacturers worldwide and channel them through Vietnam’s largest distribution network — via registered tender pathways and direct hospital relationships.
What we offer
Hospital-direct distribution
Tender wins translate into immediate placement across 1,000+ public and private hospitals and 5,000+ pharmacies nationwide, served from 4 GSP-certified warehouses operated under our GDP-certified distribution network.
Regulatory affairs & DAV submission expertise
Our regulatory affairs team handles the full registration pathway with the Drug Administration of Vietnam (DAV) — from dossier submission through post-approval lifecycle management.
Tender strategy
Under Circular 07/2024/TT-BYT on drug procurement at health facilities, we position your molecule into the appropriate tender category — Reference Drug Group for originators or Generic Groups 1–5 for generics — to optimize volume and margin, then defend the listing across subsequent hospital procurement cycles.
Local commercial team
100+ staff across 5 offices including a 20-headcount oncology specialty force at Vietnam's top cancer centers (16 reps split 8 South / 6 North / 2 Center, plus product and project management).
Who we seek
We work across three manufacturer tiers, mapped to Vietnam’s tender group structure under Circular 07/2024/TT-BYT.
P1 — Group 1 generics / SRA-listed
Generic manufacturers operating EU-GMP-compliant (or equivalent) production lines in SRA-recognized countries — EU, US, Japan, UK, Switzerland, Canada, Australia. Vietnam Generic Tender Group 1, premium positioning.
P2 — Group 2 generics / EU-GMP / PIC/S-GMP
Generic manufacturers operating EU-GMP-compliant (or equivalent) production lines in non-SRA countries — Korea, India, and other ICH/PIC-S members. Vietnam Generic Tender Group 2, balanced volume and margin profile.
P3 — WHO-GMP generics / Group 5 generics
Generic manufacturers operating WHO-GMP-certified production lines — such as India, Bangladesh and China. Drugs with bioequivalence (BE) data qualify for Vietnam Generic Tender Group 3; remaining WHO-GMP products fall into Group 5. Scale and price-led positioning.
Strategic priorities for new partnerships
Areas where we are actively seeking additional manufacturer partners based on Vietnam tender demand and gaps in our current portfolio:
Tell us your molecule
We’ll send a personalized 2-page Vietnam Market Entry Brief — tender volume, current originator, regulatory path, and our distribution capability for that therapeutic area.
Request a brief